Etern Biopharma (Shanghai) Co. Ltd. has described bicyclic heteroaryl compounds acting as transcriptional coactivator YAP1 and/or TAZ/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer, fibrosis and cardiovascular disorders.
Vertex Pharmaceuticals Inc. has divulged cystic fibrosis transmembrane conductance regulator (CFTR) modulators reported to be useful for the treatment of cystic fibrosis.
Beigene Ltd. has identified heterocyclic compounds acting as E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of hematologic cancer and glioblastoma.
Shenzhen Forward Pharmaceuticals Co. Ltd. has synthesized quinazoline derivatives acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer, particularly lung cancer.
Xtalpi Inc. and Parthenon Therapeutics Inc. (now known as Incendia Therapeutics Inc.) have entered into a collaboration to discover novel therapeutic antibodies for the treatment of solid tumors.
Researchers from the MD Anderson Cancer Center presented data from a study that assessed the tumor microenvironment (TME) of adenoid cystic carcinoma (ACC) with the aim of identifying novel therapeutic targets for ACC.
RSS
